Cheng Shan Liu

US Patent:

8025879, Sep 27, 2011

Filed:

Jul 21, 2009

Appl. No.:

12/507044

Inventors:

Cheng Liu - Richmond CA, US
Jingyi Xiang - Walnut Creek CA, US
Su Yan - Albany CA, US
Pei Wang - Fremont CA, US
Wei Chan Tai - Emeryville CA, US

Assignee:

Eureka Therapeutics, Inc. - Emeryville CA

International Classification:

C07K 14/00
C07K 16/18

US Classification:

4241331, 5303873, 530395

Abstract:

The present disclosure provides compositions and methods comprising cells producing glycoproteins with variant glycosylation patterns. The methods and compositions may be used in producing antibodies and proteins of therapeutic value.

US Patent:

8080415, Dec 20, 2011

Filed:

Jul 21, 2009

Appl. No.:

12/507046

Inventors:

Cheng Liu - Richmond CA, US
Jingyi Xiang - Walnut Creek CA, US
Su Yan - Albany CA, US
Pei Wang - Fremont CA, US
Wei Chan Tai - Emeryville CA, US

Assignee:

Eureka Therapeutics, Inc. - Emeryville CA

International Classification:

C12M 1/00

US Classification:

435334, 4352891, 435358

Abstract:

The present disclosure provides compositions and methods comprising cells producing glycoproteins with variant glycosylation patterns. The methods and compositions may be used in producing antibodies and proteins of therapeutic value.

US Patent:

8084222, Dec 27, 2011

Filed:

Jul 21, 2009

Appl. No.:

12/507051

Inventors:

Cheng Liu - Richmond CA, US
Jingyi Xiang - Walnut Creek CA, US
Su Yan - Albany CA, US
Pei Wang - Fremont CA, US
Wei Chan Tai - Emeryville CA, US

Assignee:

Eureka Therapeutics, Inc. - Emeryville CA

International Classification:

C12Q 1/68
G01N 33/53

US Classification:

435 721, 435 29

Abstract:

The present disclosure provides compositions and methods comprising cells producing glycoproteins with variant glycosylation patterns. The methods and compositions may be used in producing antibodies and proteins of therapeutic value.

US Patent:

8295882, Oct 23, 2012

Filed:

Oct 18, 2010

Appl. No.:

12/906277

Inventors:

James Fan - San Ramon CA, US
Richard Kuo - Mountain View CA, US
Cheng P. Liu - Duluth GA, US

Assignee:

AT&T Intellectual Property I, LP - Atlanta GA

International Classification:

H04B 1/38

US Classification:

455558, 455415, 455418, 4554351

Abstract:

Systems, methods, and computer program products are for managing access to a femtocell coverage area. An exemplary method includes storing in a memory component a first identifier corresponding to a subscribed service of a communication device and a second identifier corresponding to a user of the communication device, and granting access to the femtocell coverage area using the second identifier.

US Patent:

20070225355, Sep 27, 2007

Filed:

Jun 23, 2005

Appl. No.:

11/571321

Inventors:

Cheng Liu - Richmond CA, US

Assignee:

Elixirin Corporation - Richmond CA

International Classification:

A61K 31/385
C07D 339/04
C12N 1/02
C12N 1/26

US Classification:

514440000, 435248000, 435261000, 549037000

Abstract:

This invention relates to dietary compositions and to methods for modifying cellular metabolism, metabolic production of reactive oxygen species and the resulting level of reactive oxygen species. The invention is drawn to a composition comprising a combination of carnitine, lipoic acid and polyphenol, which has the effect of enhancing metabolism and reducing oxygen species at the same time. When the composition is fed to older animals, the animals will have improved metabolism at the cellular level and a reduction of oxidative stress. The invention is also drawn to a method of oral administration of carnitine, lipoic acid and polyphenol to a mammalian host, at an effective dose necessary to affect enhanced metabolic processes and reduced oxygen species in animals including humans.

US Patent:

20090155821, Jun 18, 2009

Filed:

Jan 4, 2007

Appl. No.:

12/159827

Inventors:

John Kunich - San Leandro CA, US
Cheng Liu - Richmond CA, US

International Classification:

G01N 33/574
G01N 33/566

US Classification:

435 723, 435 72

Abstract:

Methods for detecting antibody dependent cellular cytotoxicity (ADCC) are described herein. The methods are label-free, and can be performed in real time on adherent cells. The methods can include, for example, (a) monitoring the impedance between electrodes on a non-conducting substrate that supports the growth of target cells in an assay medium; and (b) adding effector cells and an antibody that binds to the target cells to the assay medium; wherein any decrease in the impedance between the electrodes on the substrate following addition of the effector cells and the antibody is indicative of ADCC function having been effected in the assay medium.

US Patent:

20090246208, Oct 1, 2009

Filed:

Jan 4, 2007

Appl. No.:

12/159665

Inventors:

Michael Kavanaugh - Orinda CA, US
Cheng Liu - Richmond CA, US

Assignee:

Novartis AG - Basel
Xoma Technology Ltd. - Hamilton

International Classification:

A61K 39/395
A61P 19/00

US Classification:

4241581

Abstract:

Methods for preventing and treating osteolysis, cancer metastasis and bone loss associated with cancer metastasis by administering an M-CSF-antagonist in combination with a therapeutic agent to a subject are provided.

US Patent:

20090324604, Dec 31, 2009

Filed:

Jan 6, 2005

Appl. No.:

10/585459

Inventors:

Cheng Liu - Emeryville CA, US
Deborah Lee Zimmerman - Emeryville CA, US
Gregory M. Harrowe - Eugene OR, US
Kirston Koths - Emeryville CA, US
William M. Kavanaugh - Emeryville CA, US
Li Long - Lafayette CA, US
Arnold Horwitz - San Leandro CA, US

Assignee:

CHIRON CORPORATION - Emeryville CA
XOMA Technology Ltd. - Hamilton

International Classification:

A61K 39/395
C07K 16/00
A61P 35/00
A61P 19/00

US Classification:

4241451, 5303873, 53038815, 53038823

Abstract:

M-CSF-specific antibody RX1 is provided, along with pharmaceutical compositions containing antibody RX1, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease.